Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: Incidence, clinical features, and risk factors

Annals of Surgical Oncology

Volumn 19, Issue 5, 2012, Pages 1609-1617

  Ito, Kaori ^a,b   Ito, Hiromichi ^a,b   Kemeny, Nancy E ^a   Gonen, Mithat ^a   Allen, Peter J ^a   Paty, Philip B ^a   Fong, Yuman ^a   DeMatteo, Ronald P ^a   Blumgart, Leslie H ^a   Jarnagin, William R ^a   D'Angelica, Michael I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; BILIARY TRACT DISEASE; BILIARY TRACT SCLEROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; COMORBIDITY; FEMALE; HEPATIC DUCT; HUMAN; INCIDENCE; INFUSION PUMP; INOPERABLE CANCER; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; RISK FACTOR; SCLEROSIS;

ADULT; AGED; AGED, 80 AND OVER; BILIARY TRACT DISEASES; CAUSALITY; COHORT STUDIES; COLORECTAL NEOPLASMS; COMORBIDITY; DILATATION; FEMALE; FLOXURIDINE; HEPATECTOMY; HUMANS; HYPERBILIRUBINEMIA; INCIDENCE; INFUSIONS, INTRA-ARTERIAL; LIGATION; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; STENTS; SURVIVAL RATE; YOUNG ADULT;

EID: 84862509821     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2102-8     Document Type: Article

References (36)

1. Kemeny N, Fata F. Hepatic-arterial chemotherapy. Lancet Oncol. 2001;2:418-28. (Pubitemid 33585946)
2. Kemeny N, Capanu M, D'Angelica M, et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009;20:1236-41.
3. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039-48. (Pubitemid 30035952)
4. Kemeny N, Jarnagin W, Gonen M, et al. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol. 2003;21:3303-9. (Pubitemid 46606264)
5. Kemeny N, Conti JA, Sigurdson E, et al. A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases. Cancer. 1993;71:1964-71. (Pubitemid 23068542)
6. Kemeny NE, Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27:3465-71.
7. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24:1395-403. (Pubitemid 46622004)
8. Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005;23:4888-96. (Pubitemid 46223994)
9. Kemeny N, Eid A, Stockman J, et al. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. JSurgOncol. 2005;91:97-101. (Pubitemid 41077048)
10. Kemeny N, Gonen M, Sullivan D, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol. 2001;19:2687-95. (Pubitemid 32441374)
11. Kemeny N, Conti JA, Cohen A, et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 1994;12:2288-95. (Pubitemid 24346697)
12. Kemeny N, Seiter K, Conti JA, et al. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. Cancer. 1994;73:1134-42. (Pubitemid 24061606)
13. Allen PJ, Nissan A, Picon AI, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005;201:57-65. (Pubitemid 40840564)
14. Daly JM, Kemeny N, Oderman P, Botet J. Long-term hepatic arterial infusion chemotherapy. Anatomic considerations, operative technique, and treatment morbidity. Arch Surg. 1984;119:936-41. (Pubitemid 14053587)
15. Kemeny MM, Battifora H, Blayney DW, et al. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg. 1985;202:176-81. (Pubitemid 15041717)
16. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med. 1987;107:459-65. (Pubitemid 17149758)
17. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987;206:685-93. (Pubitemid 18056182)
18. Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol. 1989;7:1646-54. (Pubitemid 19272834)
19. Martin JK, Jr., O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg. 1990;125:1022-7. (Pubitemid 20249340)
20. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol. 1992;10:1112-8.
21. Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2000;18:243-54. (Pubitemid 30056411)
22. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol. 2002;20:1499-505. (Pubitemid 34260528)
23. Martin RC, Edwards MJ, McMasters KM. Morbidity of adjuvant hepatic arterial infusion pump chemotherapy in the management of colorectal cancer metastatic to the liver. Am J Surg. 2004;188:714-21.
24. Ludwig J, Kim CH, Wiesner RH, Krom RA. Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy? Hepatology. 1989;9:215-8. (Pubitemid 19063304)
25. Michels NA. Newer anatomy of the liver and its variant blood supply and collateral circulation. Am J Surg. 1966;112:337-47.
26. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-18.
27. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med. 1995;332:924-33.
28. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology. 1999;30:325-32. (Pubitemid 29300604)
29. Lillemoe KD. Benign post-operative bile duct strictures. Baillieres Clin Gastroenterol. 1997;11:749-79. (Pubitemid 28058797)
30. Cantwell CP, Pena CS, Gervais DA, Hahn PF, Dawson SL, Mueller PR. Thirty years' experience with balloon dilation of benign postoperative biliary strictures: long-term outcomes. Radiology. 2008;249:1050-7.
31. Costamagna G, Shah SK, Tringali A. Current management of postoperative complications and benign biliary strictures. Gastrointest Endosc Clin N Am. 2003;13:635-48. (Pubitemid 37444937)
32. Goere D, Deshaies I, de Baere T, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010;251:686-91.
33. Tsimberidou AM, Fu S, Ng C, et al. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer. 2010;116:4086-94.
34. Bouchahda M, Adam R, Giacchetti S, et al. Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer. 2009;115:4990-9.
35. Boige V, Malka D, Elias D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2008;15:219-26.
36. Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005;23:4881-7. (Pubitemid 46223993)